BioRestorative Therapies demonstrated significant progress with their BRTX-100 program, achieving FDA Fast Track designation and clearance for a new clinical trial, positioning the company strongly in the cell-based therapy market. However, financial challenges and a decline in revenue remain concerns.

Company Guidance -

Q2 2025

During the first quarter of 2025, BioRestorative Therapies provided guidance on various financial and operational metrics. The company reported a revenue of approximately $25,000, a decrease from $35,000 in the same period the previous year, but highlighted $150,000 in deferred revenues, indicating timing differences in revenue recognition. The loss from operations rose to $4.8 million from $4.1 million in the first quarter of 2024, and the net loss increased to $5.3 million or $0.64 per share, compared to $2.2 million or $0.33 per share in the prior year, primarily due to a previous gain on warrant exchange. Despite the increased losses, the company maintained a solid financial position with $9.1 million in cash, cash equivalents, and marketable securities, and no outstanding debt. Operationally, the company achieved two significant FDA milestones for its lead candidate, BRTX-100, including a Fast Track designation for its chronic lumbar disc disease program and clearance for a Phase II trial in chronic cervical discogenic pain, while continuing to advance its preclinical ThermoStem program targeting obesity and metabolic disorders.

FDA Fast Track Designation for BRTX-100

BioRestorative Therapies received FDA Fast Track designation for their BRTX-100 program targeting chronic lumbar disc disease, facilitating development and expediting review processes.

FDA Clearance for Phase II Clinical Trial in cCDP

The FDA cleared BioRestorative's investigational drug application for a Phase II clinical trial of BRTX-100 in chronic cervical discogenic pain, marking it as the first stem cell-based product candidate to be evaluated in cervical degeneration disc disease.

Strong Financial Position

The company ended the quarter with $9.1 million in cash, cash equivalents, and marketable securities, with no outstanding debt.

Positive Preliminary Data for BRTX-100

Preliminary blinded data shows positive trends in safety and efficacy for BRTX-100 in treating chronic lumbar disc disease, with no serious adverse events reported.

Expansion of ThermoStem IP Portfolio

BioRestorative expanded its intellectual property estate for ThermoStem, covering both U.S. and international markets, to protect its potential treatments for obesity and metabolic disorders.

BioRestorative Therapies (BRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BRTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 19, 2025	2025 (Q2)	-0.37 / -	-0.5	―	―	―
May 14, 2025	2025 (Q1)	-0.33 / -0.64	-0.33	-93.94% (-0.31)	―
Mar 27, 2025	2024 (Q4)	-0.34 / -0.20	-0.6	66.67% (+0.40)	―
Nov 12, 2024	2024 (Q3)	-0.43 / -0.13	-0.64	79.69% (+0.51)	―
Aug 13, 2024	2024 (Q2)	-0.57 / -0.50	-0.77	35.06% (+0.27)	―	―
May 14, 2024	2024 (Q1)	-0.52 / -0.33	-1.53	78.43% (+1.20)	―	―
May 15, 2018	2018 (Q1)	- / -1560.00	-2240	30.36% (+680.00)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BRTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$1.71	$1.67	-2.34%
Mar 27, 2025	$1.83	$1.81	-1.09%
Nov 12, 2024	$1.64	$1.54	-6.10%
Aug 13, 2024	$1.41	$1.40	-0.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioRestorative Therapies (BRTX) report earnings?

BioRestorative Therapies (BRTX) is schdueled to report earning on Aug 19, 2025, After Close (Confirmed).

What is BioRestorative Therapies (BRTX) earnings time?

BioRestorative Therapies (BRTX) earnings time is at Aug 19, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BRTX EPS forecast?

BRTX EPS forecast for the fiscal quarter 2025 (Q2) is -0.37.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing